Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis
Anuraag Jena, Deepak James, Anupam Singh, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 20, Iss. 7, pp. 1456-1479.e18
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era
Gerasimos Evangelatos, Giorgos Bamias, George D. Kitas, et al.
Rheumatology International (2022) Vol. 42, Iss. 9, pp. 1493-1511
Open Access | Times Cited: 61
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study
James L. Alexander, Zhigang Liu, Diana Muñoz Sandoval, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 11, pp. 1005-1015
Open Access | Times Cited: 50
Clinical guidelines. Crohn’s disease (К50), adults
Yu. A. Shelygin, В. Т. Ивашкин, С. И. Ачкасов, et al.
Koloproktologia (2023) Vol. 22, Iss. 3, pp. 10-49
Open Access | Times Cited: 22
Vaccination for the Prevention of Infection among Immunocompromised Patients: A Concise Review of Recent Systematic Reviews
Kay Choong See
Vaccines (2022) Vol. 10, Iss. 5, pp. 800-800
Open Access | Times Cited: 33
Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
Trung Tran, Eline Benno Vaage, Adi Mehta, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 28
Understanding the time-driven shifts of vaccine effectiveness against any and severe COVID-19 before and after the surge of Omicron variants within 2.5 years of vaccination: A meta-regression
Marek Petráš, D Janovská, Danuše Lomozová, et al.
International Journal of Infectious Diseases (2024) Vol. 142, pp. 106986-106986
Open Access | Times Cited: 5
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic
Simeng Lin, Louis Ho Shing Lau, Neil Chanchlani, et al.
Gut (2022) Vol. 71, Iss. 7, pp. 1426-1439
Open Access | Times Cited: 25
Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease
Erica J. Brenner, Kimberly N. Weaver, Xian Zhang, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 7, pp. 1475-1486.e4
Closed Access | Times Cited: 4
Impaired humoral and cellular response to primary COVID‐19 vaccination in patients less than 2 years after allogeneic bone marrow transplant
Sam M. Murray, Maria Chiara Barbanti, Cori Campbell, et al.
British Journal of Haematology (2022) Vol. 198, Iss. 4, pp. 668-679
Open Access | Times Cited: 18
mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses
Jet van den Dijssel, Mariël C Duurland, Veronique A. L. Konijn, et al.
Journal of Autoimmunity (2024) Vol. 144, pp. 103175-103175
Open Access | Times Cited: 3
Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre la importancia, el cribado y la vacunación en pacientes con enfermedad inflamatoria intestinal
R Ferreiro-Iglesias, Marta Piqueras, E Ricart, et al.
Gastroenterología y Hepatología (2022) Vol. 45, Iss. 10, pp. 805-818
Open Access | Times Cited: 17
Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease
Joshua Quan, Christopher Ma, Remo Panaccione, et al.
Gut (2022) Vol. 72, Iss. 4, pp. 802-804
Open Access | Times Cited: 17
BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: a monocentric real-life study
Raffaele Pellegrino, Gianluca Pellino, Lucio Selvaggi, et al.
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 10, pp. 1243-1252
Closed Access | Times Cited: 16
Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: a meta-analysis and meta-regression
Marek Petráš, Roman Máčalík, D Janovská, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 16
Crohn's disease and clinical management today: How it does?
Ronaldo Teixeira da Silva Júnior, Jonathan Santos Apolonio, Jéssica Oliveira de Souza Nascimento, et al.
World Journal of Methodology (2023) Vol. 13, Iss. 5, pp. 399-413
Open Access | Times Cited: 9
Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines among Patients with Immune-Mediated Dermatological Diseases: A Systematic Review and Meta-analysis
Sonphet Chirasuthat, Yanisa Ratanapokasatit, Kunlawat Thadanipon, et al.
Acta Dermato Venereologica (2024) Vol. 104, pp. adv40009-adv40009
Open Access | Times Cited: 2
COVID-19 Vaccination in Inflammatory Bowel Disease (IBD)
Aleksandra Kubas, Ewa Małecka‐Panas
Journal of Clinical Medicine (2022) Vol. 11, Iss. 9, pp. 2676-2676
Open Access | Times Cited: 13
Systemic and T cell‐associated responses to SARS‐CoV‐2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS‐CoV‐2
Simon Woelfel, Joel Dütschler, Marius König, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 1, pp. 103-116
Open Access | Times Cited: 13
A bibliometric analysis of inflammatory bowel disease and COVID-19 researches
Fangfei Wang, Jinliang Xie, Huifang Xiong, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 7
Impact of COVID-19 in individuals with and without pre-existent digestive disorders with a particular focus on elderly patients
Alfredo Papa, Marcello Covino, Sara Sofia De Lucia, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 26, pp. 4099-4119
Open Access | Times Cited: 7
Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews
Thuan Tong Tan, Heng Joo Ng, Barnaby Edward Young, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 341-365
Open Access | Times Cited: 6
STAR SIGN study: Evaluation of COVID‐19 vaccine efficacy against the SARS‐CoV‐2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease
Simon Woelfel, Joel Dütschler, Marius König, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 58, Iss. 7, pp. 678-691
Closed Access | Times Cited: 6
COVID-19 Vaccine Booster Shot Preserves T Cells Immune Response Based on Interferon-Gamma Release Assay in Inflammatory Bowel Disease (IBD) Patients on Anti-TNFα Treatment
Grazia Pavia, Rocco Spagnuolo, Angela Quirino, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 591-591
Open Access | Times Cited: 5
Differences in Coronavirus disease - 19 vaccination related side effects in patients with ulcerative colitis and Crohn’s disease in Japan
Haruka Miyazaki, Daisuke Watanabe, Yuki Ito, et al.
Indian Journal of Gastroenterology (2023) Vol. 42, Iss. 5, pp. 701-707
Closed Access | Times Cited: 5
Response to COVID‐19 vaccine is reduced in patients with inflammatory bowel disease, but improved with additional dose
Hisashi Shiga, Yoichi Kakuta, Kumiko An, et al.
Journal of Gastroenterology and Hepatology (2022) Vol. 38, Iss. 1, pp. 44-51
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top